Premium
Identification of metabolic markers in patients with type 2 Diabetes by Ultrafast gas chromatography coupled to electronic nose. A pilot study
Author(s) -
MéndezRodríguez Karen Beatriz,
FigueroaVega Nicté,
IlizaliturriHernandez César Arturo,
CardonaAlvarado Mónica,
BorjasGarcía Jaime Antonio,
Kornhauser Carlos,
Malacara Juan Manuel,
FloresRamírez Rogelio,
PérezVázquez Francisco Javier
Publication year - 2020
Publication title -
biomedical chromatography
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.4
H-Index - 65
eISSN - 1099-0801
pISSN - 0269-3879
DOI - 10.1002/bmc.4956
Subject(s) - electronic nose , urine , chemistry , metabolomics , type 2 diabetes , chromatography , gas chromatography , diabetes mellitus , population , medicine , endocrinology , psychology , biochemistry , environmental health , neuroscience
Metabolomics is a potential tool for the discovery of new biomarkers in the early diagnosis of diseases. An ultra‐fast gas chromatography system equipped to an electronic nose detector (FGC eNose) was used to identify the metabolomic profile of Volatile Organic Compounds (VOCs) in type 2 diabetes (T2D) urine from Mexican population. A cross‐sectional, comparative, and clinical study with translational approach was performed. We recruited twenty T2D patients and twenty‐one healthy subjects. Urine samples were taken and analyzed by FGC eNose. Eighty‐eight compounds were identified through Kovats's indexes. A natural variation of 30% between the metabolites, expressed by study groups, was observed in Principal Component 1 and 2 with a significant difference ( p < 0.001). The model, performed through a Canonical Analysis of Principal coordinated (CAP), allowed a correct classification of 84.6% between healthy and T2D patients, with a 15.4% error. The metabolites 2‐propenal, 2‐propanol, butane‐ 2,3‐dione and 2‐methylpropanal, were increased in patients with T2D, and they were strongly correlated with discrimination between clinically healthy people and T2D patients. This study identified metabolites in urine through FGC eNose that can be used as biomarkers in the identification of T2D patients. However, more studies are needed for its implementation in clinical practice.